| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥2160.2B | ¥1982.1B | +9.0% |
| Operating Income | ¥94.2B | ¥110.3B | -14.7% |
| Ordinary Income | ¥94.9B | ¥113.6B | -16.5% |
| Net Income | ¥53.0B | ¥57.7B | +32.6% |
| ROE | 9.4% | 9.3% | - |
Quol Holdings Co., Ltd. FY2025 Q3 (9-month) results: Revenue 216.0B yen (+9.0% YoY), Operating Income 9.4B yen (-14.7% YoY), Ordinary Income 9.5B yen (-16.5% YoY), Net Income 5.3B yen (-8.1% YoY). The company achieved record-high revenue and quarterly net income on a cumulative basis, driven by expanded consolidation of Daiichi Sankyo Espha (ownership increased from 51% to 80% in Q1) and pharmacy business technical fee improvements. However, operating profitability declined as the pharmaceutical segment changed expense allocation methodology, concentrating certain costs in Q3 that will normalize over the full year. Gross margin remained at 13.2%, reflecting competitive pricing pressure in the pharmacy business. Full-year guidance projects revenue of 280.0B yen (+6.1% YoY) with operating income recovery to 15.5B yen (+15.1% YoY), indicating expected Q4 margin improvement.
Revenue growth of 9.0% was primarily driven by three factors: (1) increased consolidation effect from Daiichi Sankyo Espha pharmaceutical business (+23.1% segment revenue), (2) technical fee per prescription improvement in pharmacy business due to 94.8% adoption of Medical DX promotion system add-on and 90.0% generic drug utilization rate achievement, and (3) CSO outsourcing demand expansion in BPO business (+4.8% segment revenue). The pharmaceutical segment's prior-year launched products (rivaroxaban, loxoprofen sodium tape, hydroxychloroquine sulfate) contributed significantly with shipment volumes up 15% YoY.
Operating income declined 14.7% despite revenue growth, primarily due to a non-recurring accounting methodology change in the pharmaceutical segment. Starting Q3, certain expenses previously recognized evenly throughout the year were shifted to back-half weighting, concentrating costs in Q3. Management emphasized this represents timing differences that will normalize in full-year results. Additionally, pharmacy segment operating income decreased 2.3% as prescription volume declined due to longer prescription periods, partially offsetting technical fee gains. Selling, general and administrative expenses increased to 19.1B yen, absorbing margin gains from revenue growth.
The gap between ordinary income (9.5B yen, -16.5%) and net income (5.3B yen, -8.1%) narrowed compared to operating income decline, reflecting a lower effective tax burden in Q3 (tax rate 43.5% on pre-tax income of 9.4B yen resulted in 4.1B yen tax expense). Net income to owners was 4.7B yen (+32.6% YoY), benefiting from reduced non-controlling interest allocation following the Daiichi Sankyo Espha ownership increase.
This represents a revenue up, profit down pattern, with structural drivers (business expansion, fee structure improvements) supporting top-line growth, but temporary expense allocation changes and prescription volume headwinds weighing on near-term profitability. Operating margin compressed from 5.6% to 4.4%.
Pharmacy Business (core business, 61.3% of revenue): Revenue 132.4B yen (+2.8% YoY), Operating Income 6.9B yen (-2.3% YoY), operating margin 5.2%. This segment generated the largest revenue contribution. Technical fee per prescription improved through 94.8% adoption rate of Medical DX promotion system add-on (implemented June 2024 revision) and achievement of 90.0% generic drug utilization rate. However, prescription volume declined due to longer prescription periods and other structural factors, resulting in decreased profit despite higher per-prescription fees. Store count reached 942 (8 new openings, 1 M&A, 2 closures). Margin compression reflected the challenge of volume decline offsetting quality improvements.
BPO Business: Revenue 10.5B yen (+4.8% YoY), Operating Income 1.3B yen (+9.9% YoY), operating margin 12.8%. This segment delivered the strongest profit growth rate and highest margin. Revenue expansion was driven by increased MR (medical representative) dispatch volume in CSO business, reflecting pharmaceutical companies' growing preference for outsourced CMR (contract MR) amid industry-wide MR headcount reduction. Apoplus Station achieved record-high CMR count in FY2025. The segment is cultivating specialized MRs in oncology, immunology, and central nervous system therapeutic areas to enhance value-add. Margin expansion reflected operating leverage on dispatch model.
Pharmaceutical Business: Revenue 73.1B yen (+23.1% YoY), Operating Income 4.0B yen (-26.0% YoY), operating margin 5.5%. Revenue growth was the strongest among segments, driven by three products launched in prior fiscal year (three components, seven SKUs) gaining formulary adoption. Shipment volume for major products increased 15% YoY. However, operating income declined sharply due to expense allocation methodology change beginning Q3, where certain expenses previously spread throughout the year were shifted to back-half concentration. Management stated this timing difference will normalize over the full year. New product launches are scheduled (abiraterone acetate in December 2025, prasugrel four SKUs in March 2026), positioning for continued growth. The segment's expanded consolidation (ownership 51% to 80%) significantly influenced group results.
Segment margin comparison shows BPO business operating at highest margin (12.8%), followed by pharmaceutical (5.5%) and pharmacy (5.2%). The pharmaceutical segment's temporary margin compression due to expense timing is expected to reverse in Q4, while pharmacy margin pressure from volume decline represents a more structural challenge requiring ongoing technical fee optimization and portfolio management.
Profitability: ROE 8.2% (PY 8.2% for comparable period, indicating stability despite profit decline), Operating Margin 4.4% (PY 5.6%, decline of 1.2pt reflecting expense timing and volume headwinds), Net Profit Margin 2.2% (in line with prior periods). EBIT Margin 4.4% with interest coverage ratio of 36.6x indicating ample debt servicing capacity.
Cash Quality: Detailed operating cash flow data not disclosed in quarterly statement, limiting full assessment. Cash and deposits stood at 21.1B yen against short-term borrowings of 15.8B yen, providing cash-to-short-term debt coverage of 1.33x.
Financial Health: Equity Ratio 36.2% (PY 38.9%, decrease of 2.7pt driven by increased consolidation and minority interest reduction), Current Ratio 0.76x (below 1.0x indicating working capital deficit of -19.7B yen), Quick Ratio 0.68x. Financial Leverage 2.76x. Debt-to-Capital Ratio 34.3%. Net Debt to EBITDA unavailable due to limited cash flow disclosure.
Asset Efficiency: Total Asset Turnover 1.38x, indicating moderate asset productivity. Receivables increased 25.6% YoY, inventories increased 51.2% YoY (reflecting pharmaceutical segment consolidation expansion), and payables increased 31.2% YoY, resulting in working capital pressure.
Balance Sheet Structure: Goodwill of 36.8B yen represents 65% of equity, and intangible assets total 66.2B yen (42.3% of total assets), creating elevated impairment risk concentration that requires ongoing monitoring.
Operating CF: Detailed operating cash flow data was not disclosed in the quarterly financial statements, preventing calculation of OCF-to-Net Income ratio. However, working capital changes indicate cash generation pressure. Receivables increased 5.5B yen (+25.6%), inventories increased 2.3B yen (+51.2%), and payables increased 9.6B yen (+31.2%). The inventory surge reflects pharmaceutical segment consolidation expansion and potential stock-building ahead of new product launches. Receivables growth outpaced revenue growth (25.6% vs 9.0%), suggesting collection cycle extension or sales mix shift toward longer-payment customers. Payables growth provides partial offset through extended payment terms.
Investing CF: Specific investing cash flow data not disclosed. Capital expenditure relative to depreciation and amortization cannot be calculated from available data. The company completed one M&A transaction (Hikari 8 stores in January 2026) and opened 8 new pharmacy stores, indicating continued growth investment.
Financing CF: Detailed financing cash flow not disclosed. Long-term borrowings decreased 5.4B yen (-28.2%) indicating debt repayment, while short-term debt structure remains concentrated (53.4% of total liabilities are current). Interim dividend of 17 yen per share was paid.
FCF: Cannot be calculated due to limited cash flow disclosure.
Cash generation: Assessment is "Needs Monitoring" due to working capital deterioration (receivables and inventory growth outpacing payables), current ratio below 1.0x, and lack of detailed operating cash flow visibility. The company maintains 21.1B yen cash reserves providing near-term liquidity buffer, but working capital trends require improvement to ensure sustainable cash generation supporting both growth investment and shareholder returns.
Ordinary vs Net Income: Ordinary income of 9.5B yen declined 16.5% YoY, slightly more than operating income decline of 14.7%, with the gap attributable to non-operating items (net non-operating expense of 0.1B yen). The larger divergence between operating profit and net income relates to tax burden, with effective tax rate of 43.5% on pre-tax income of 9.4B yen. This elevated effective rate (vs. statutory rate of approximately 30%) warrants further disclosure review regarding temporary differences or non-deductible items.
Non-recurring items: The pharmaceutical segment expense allocation methodology change represents a material timing difference affecting quarterly comparability but not full-year economics. This should be viewed as a non-recurring quarterly distortion rather than sustainable margin pressure. Management explicitly stated the approach shifts certain expenses from even quarterly distribution to back-half weighting, with full-year results unaffected. Excluding this timing impact, underlying pharmaceutical operating profit would have been materially higher in Q3.
Accruals concern: Net income of 5.3B yen cannot be directly compared to operating cash flow due to limited OCF disclosure. However, working capital deterioration (receivables +5.5B yen, inventory +2.3B yen net of payables +9.6B yen increase) suggests cash earnings trail reported net income, indicating lower earnings quality in the quarter. The receivables growth rate of 25.6% significantly exceeding revenue growth of 9.0% (ratio of 2.8x) raises questions about collection efficiency or sales recognition timing that should normalize in subsequent quarters.
Overall earnings quality is mixed: (1) pharmaceutical timing differences are temporary and will reverse, (2) underlying business drivers (technical fee improvements, CMR demand, new product adoption) are structural positives, but (3) working capital absorption and high effective tax rate present near-term cash quality concerns requiring monitoring.
Full-year guidance: Revenue 280.0B yen, Operating Income 15.5B yen, Ordinary Income 15.6B yen, Net Income 7.0B yen, annual dividend 23 yen per share (unchanged from initial guidance).
Progress rate vs full-year guidance at Q3 (9-month point, standard expectation 75%): Revenue 77.2% (on track), Operating Income 60.7% (below standard by 14.3pt), Ordinary Income 60.8% (below standard by 14.2pt), Net Income 66.7% (below standard by 8.3pt).
Operating income progress significantly lags due to Q3 pharmaceutical segment expense concentration from methodology change. Management guidance implies Q4 operating income of 6.1B yen (vs. Q1-Q3 average of 3.1B yen), representing substantial sequential recovery. This requires: (1) reversal of pharmaceutical timing differences as expenses normalize, (2) continued technical fee momentum in pharmacy business, and (3) seasonal strength. The implied Q4 operating margin of 8.7% would exceed Q1-Q3 average of 4.4% by 4.3pt, representing an aggressive step-up that execution risks exist around.
Net income guidance implies Q4 net income of 1.7B yen (vs. Q3 of 4.7B yen for cumulative), suggesting either conservative Q4 outlook or higher expected tax burden in Q4. The guidance implies full-year effective tax rate normalization.
No guidance revision was announced, indicating management confidence in achieving targets despite Q3 profit shortfall. Key assumptions include normalization of pharmaceutical expense timing, stable prescription volume trends in pharmacy, and successful new product launches (abiraterone acetate, prasugrel). Investors should monitor Q4 progress closely given the material margin recovery required to achieve full-year operating income target.
Dividend policy: Interim dividend of 17 yen per share was paid. Full-year guidance maintains 23 yen per share annual dividend (unchanged), implying year-end dividend of 6 yen per share (vs. prior-year year-end of 17 yen). However, based on typical practice and presentation materials indicating "year-end expected 17 yen," the total annual dividend is likely 34 yen per share (interim 17 yen + year-end 17 yen), though XBRL guidance shows 23 yen requiring clarification.
Using full-year net income guidance of 7.0B yen and assuming 37.5 million shares outstanding (approximate based on EPS guidance of 186.51 yen), total dividend payout would be approximately 863M yen (using 23 yen/share guidance) or 1,275M yen (using 34 yen/share alternative interpretation). Against 7.0B yen net income, this represents payout ratio of 12.3% (23 yen case) or 18.2% (34 yen case), both conservative levels providing ample dividend coverage.
For Q3 cumulative net income of 5.3B yen (owners: 4.7B yen), the interim dividend of 17 yen on estimated 37.5M shares represents approximately 638M yen, or 28.3% payout ratio on owners' net income basis, which is sustainable.
Share buybacks: No share repurchase program was disclosed or executed in the reporting period. Total return ratio equals dividend payout ratio.
Assessment: Dividend sustainability is strong based on payout ratio metrics. However, cash flow sustainability requires monitoring given working capital pressures and current ratio below 1.0x. The company maintains 21.1B yen in cash reserves providing near-term dividend coverage, but operating cash flow generation improvement is needed to support both dividends and growth investment requirements. The conservative payout ratios provide cushion for dividend stability even if earnings face pressure.
Near-term:
Long-term:
Industry Position (Reference - Proprietary Analysis)
Profitability: ROE 8.2% vs. Industry Median 2.9% (2025-Q3, retail sector, n=16 companies). Quol's ROE significantly exceeds industry median by 5.3pt, ranking in the upper quartile (industry IQR: 0.5%-7.4%). Operating Margin 4.4% vs. Industry Median 3.9% (IQR: 1.2%-8.9%), positioning slightly above median despite Q3 margin compression. Net Profit Margin 2.2% matches Industry Median 2.2% exactly (IQR: 0.2%-5.7%), indicating typical profitability for the sector.
Growth: Revenue Growth YoY 9.0% vs. Industry Median 3.0% (IQR: -0.1%-9.2%), placing Quol in the upper quartile for top-line expansion, reflecting pharmaceutical consolidation and technical fee improvements.
Financial Health: Equity Ratio 36.2% vs. Industry Median 56.8% (IQR: 39.2%-64.5%), indicating below-median capitalization and higher leverage positioning. Current Ratio 0.76x vs. Industry Median 1.93x (IQR: 1.48x-2.73x), representing material liquidity weakness ranking in bottom quartile, requiring near-term attention.
Efficiency: Asset Turnover 1.38x vs. Industry Median 0.95x (IQR: 0.77-1.16), demonstrating superior asset productivity in the top quartile. Receivables Turnover approximately 29.7 days (estimated from revenue and receivables) aligns with Industry Median 29.69 days (IQR: 18.60-60.48). Inventory Turnover and Payables Turnover comparison limited by data availability.
Overall: Quol demonstrates above-median profitability (ROE) and strong revenue growth relative to retail sector peers, with efficient asset utilization. However, financial health metrics (equity ratio, current ratio) rank below median, indicating balance sheet structure warrants monitoring. The company's hybrid pharmacy-pharmaceutical-BPO model creates differentiated risk-return profile vs. pure retail peers.
Note: Industry benchmarks are reference information compiled from publicly available retail sector earnings data. Quol's business model spans pharmacy retail, pharmaceutical manufacturing, and BPO services, creating some comparability limitations with pure retail sector peers.
Liquidity and Working Capital Risk (High): Current ratio of 0.76x indicates working capital deficit of 19.7B yen, with current liabilities of 81.9B yen exceeding current assets of 62.2B yen. Short-term debt represents 53.4% of total liabilities, creating refinancing risk if credit market conditions tighten. Receivables growth of 25.6% and inventory surge of 51.2% YoY have absorbed significant cash, while payables increased only 31.2%, insufficient to offset asset growth. Cash reserves of 21.1B yen provide approximately 6.6 months of coverage against average quarterly operating expenses (estimated ~3.2B yen based on SG&A), offering near-term buffer but requiring working capital cycle improvement to ensure sustainable liquidity.
Impairment Risk - Goodwill and Intangible Assets (Medium-High): Goodwill of 36.8B yen represents 65% of equity, and total intangible assets reach 66.2B yen (42.3% of total assets), creating concentrated impairment exposure. These balances primarily relate to pharmacy store acquisitions and pharmaceutical business consolidation. If cash generation from acquired businesses underperforms expectations due to continued prescription volume decline, drug price revisions, or pharmaceutical product adoption shortfalls, material impairment charges could significantly impact equity and reported earnings. Annual impairment testing and interim trigger event monitoring are critical given the concentration.
Drug Price and Reimbursement Policy Risk (Medium): The company faces ongoing drug price revision pressure with April 2025 revision scheduled and biennial revisions continuing. Pharmacy business technical fees are subject to regulatory change, with October 2025 selective treatment system for generics potentially affecting patient mix and fee structure. Pharmaceutical segment revenues depend on NHI (National Health Insurance) pricing, with newly launched products facing price negotiation uncertainty. A 5% adverse drug price revision affecting the pharmaceutical segment's 73.1B yen quarterly revenue would represent approximately 3.7B yen annual revenue headwind (1.3% of total revenue), requiring offsetting volume growth or cost efficiency. Combined with potential pharmacy reimbursement changes, regulatory policy represents ongoing structural pressure requiring active management response.
Three-pillar business model delivers diversification with mixed momentum: Quol's pharmacy-pharmaceutical-BPO structure provides revenue diversification (61% pharmacy, 34% pharmaceutical, 5% BPO by Q3 revenue), with each segment facing distinct drivers. Pharmaceutical segment revenue growth of 23.1% reflects successful new product launches and expanded consolidation, positioning this segment as the primary growth engine. BPO segment operating margin of 12.8% (highest among segments) with 9.9% profit growth demonstrates strong unit economics in the growing CMR outsourcing market. However, core pharmacy business faces structural volume headwinds (prescription count decline despite technical fee improvements), requiring portfolio optimization and strategic emphasis on higher-margin home/facility-based services to sustain contribution. The Q3 results highlight this portfolio transition, with growth concentrated in pharmaceutical and BPO while pharmacy provides stable but pressured cash generation. Long-term value creation depends on successfully scaling pharmaceutical product pipeline and BPO specialized capabilities while managing pharmacy margin compression.
Balance sheet structure creates near-term execution focus requirement: The combination of working capital deficit (current ratio 0.76x), high intangible asset concentration (42.3% of assets), and elevated goodwill-to-equity ratio (65%) creates near-term balance sheet management imperative. Working capital deterioration (receivables +25.6%, inventory +51.2% growth rates exceeding revenue growth) must reverse to sustainable cash conversion supporting both growth investment and shareholder returns. Management's ability to demonstrate Q4 operating margin recovery to full-year guidance (implying 8.7% Q4 operating margin vs. 4.4% Q1-Q3 average) will be critical test of execution capability and full-year guidance credibility. Successfully navigating the April 2025 drug price revision and October 2025 generic selective treatment system implementation while maintaining technical fee momentum in pharmacy and pharmaceutical product adoption trajectory represents key near-term execution milestones. Investors should monitor Q4 results and FY2026 guidance for evidence of sustainable margin recovery and working capital normalization before assuming full structural earnings power.
This report was automatically generated by AI integrating XBRL earnings data and PDF presentation materials as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI analysis of PDF earnings presentation
In Q3 FY March 2026, Qol Holdings achieved record-high net sales and quarterly net income attributable to owners of parent since its founding. From Q1 FY March 2026, the ownership stake in Daiichi Sankyo Espha increased from 51% to 80%, and the pharmaceuticals business has significantly contributed to the Group’s overall performance. In the pharmacy business, the technical fee unit price rose due to acquisition of the Medical DX Promotion System Development Add-on and an increased generic utilization ratio; however, revenue increased while profit declined as the number of prescription intakes fell amid longer prescription durations. In the BPO business, revenue and profit both grew as the number of dispatched MRs increased on rising demand for dispatched MRs in the CSO business. In the pharmaceuticals business, three ingredients and seven items launched in the previous fiscal year contributed significantly, but operating profit decreased due to a change in the expense recognition method from this Q3.
Q3 net sales of 2,160.25 hundred million yen (+9.0% YoY) and quarterly net income attributable to owners of parent of 46.71 hundred million yen (+32.6% YoY), both record highs since founding. Ownership in Daiichi Sankyo Espha increased from 51% to 80%, enhancing the prominence of the pharmaceuticals business. In the pharmacy business, the acquisition rate of the Medical DX Promotion System Development Add-on reached 94.8% as of December 2025, and the generic drug utilization rate achieved 90.0%. At Apo Plus Station in the BPO business, the number of CMRs in FY2025 reached an all-time high. In the pharmaceuticals business, products launched in December 2024 have penetrated medical institutions; new launches planned for Abiraterone acetate in December 2025 and four Prasugrel items in March 2026.
For the full year, the company forecasts net sales of 2,800 hundred million yen (+6.1% YoY), operating profit of 155 hundred million yen, ordinary profit of 156 hundred million yen, and net income of 70 hundred million yen. Progress through Q3 stands at 77.2% for net sales, 60.7% for operating profit, 60.8% for ordinary profit, and 66.7% for net income. Profit recovery in Q4 is key to achieving the plan. The pharmaceuticals business is expected to benefit from new product launches, the pharmacy business should continue to see technical fee improvements, and the BPO business will be supported by expanding CSO demand.
Management emphasized that while operating profit in Q3 declined in the pharmaceuticals business due to a change in expense recognition, it will be normalized on a full-year basis. In the pharmacy business, the company will review the store portfolio and expand scale through M&A and new openings, focusing on the Tokyo–Nagoya–Osaka region and strategically pursuing home and facility dispensing. In the BPO business, it will concentrate on developing specialist MRs (oncology, immunology-related, central nervous system) with the aim of creating high value-added CMRs.
Pharmacy business: Ongoing review of store strategy tailored to regional characteristics. Scale expansion centered on the Tokyo–Nagoya–Osaka region, with a strategic focus on home and facility dispensing. Pharmacy business: In light of a buoyant M&A market, conduct deal selection emphasizing investment efficiency. In January 2026, acquired the business of eight stores from Hikari Co., Ltd. Pharmaceuticals business: Total shipment volumes by listing year grew +15% YoY across key products. Products launched in December 2024 (Rivaroxaban, Loxoprofen Na tape, Hydroxychloroquine sulfate) contribute for the full year. BPO business: Focus on developing specialist MRs (oncology, immunology-related, central nervous system) in the CSO business; the number of CMRs at Apo Plus Station in FY2025 reached a record high. Sustainability promotion: Obtained SBTi validation and set 2030 greenhouse gas emissions reduction targets (Scopes 1+2: 42% reduction, Scope 3: 25% reduction). Newly included in ESG investment indices.
Pharmacy business: Technical fees may fluctuate quarterly due to revisions to dispensing fees and the Selected Medical Care system. Pharmacy business: Risk of a decrease in the number of prescription intakes due to longer prescription durations. Pharmaceuticals business: Potential for profit volatility by quarter due to changes in expense recognition. Pharmaceuticals business: Risk that adoption of products launched in December 2024 by medical institutions falls short of expectations. Company-wide: Risk of earnings pressure from NHI drug price revisions (April 2025 and April 2026).